- Home
- MSB vs AUTL Comparison
MSB vs AUTL Comparison
Compare MSB & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSB | AUTL |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.0M | 431.2M |
| IPO Year | 1995 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MSB | AUTL |
|---|---|---|
| Price | $31.89 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 48.3K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | ★ 391.29 | 28.33 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $98,595,651.00 | $10,120,000.00 |
| Revenue This Year | N/A | $669.62 |
| Revenue Next Year | N/A | $79.78 |
| P/E Ratio | $37.20 | ★ N/A |
| Revenue Growth | 331.26 | ★ 496.00 |
| 52 Week Low | $22.55 | $1.11 |
| 52 Week High | $42.38 | $2.70 |
Technical Indicators
Market Signals| Indicator | MSB | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 40.70 |
| Support Level | $28.62 | $1.27 |
| Resistance Level | $32.94 | $1.52 |
| Average True Range (ATR) | 2.11 | 0.11 |
| MACD | 0.18 | -0.03 |
| Stochastic Oscillator | 54.55 | 0.96 |
Price Performance
Historical ComparisonAbout MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.